Novartis loses bid to block US Entresto generic through 2026 By Blake Brittain July 11, 202510:10 AM PDTUpdated July 11, 2025 ...

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart ...

A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto.

Entresto brought in $7.8 billion in 2024, accounting for around 15% of the company's overall global sales.

A U.S. federal judge rejected Novartis' efforts to block the launch of a generic version of Entresto, its blockbuster cardiovascular disease drug, per a FirstWord PHARMA report.

The Third Circuit and Federal Circuit this week turned back Novartis’s requests for injunctions to block a version of its heart failure medication Entresto from generic maker MSN Laboratories ...

Novartis will present 19 abstracts at the 2025 European Society of Cardiology (ESC) Congress in Madrid, showcasing new findings across its cardio ...

For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to an 11% increase for the group as a whole to $14.05 billion.